At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
D-Cycloserine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Effects of Post-Session Administration of D-cycloserine On Exposure Therapy Outcomes
In Brief
A Phase 3 clinical trial evaluating Individual Cognitive Behavioral Therapy (CBT), D-Cycloserine, and 1 other intervention for Phobic Disorders. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the utility of post-session administration of D-cycloserine to enhance fear extinction in a sample of people with acrophobia who will be treated with CBT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhobic Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedApr 2010
Primary CompletionJul 2011
TodayJul 2026
First PostedApr 13, 2010
Enrollment StartApr 1, 2010
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.2 years ago
Interventions
Individual Cognitive Behavioral Therapy (CBT)behavioral
The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
D-Cycloserinedrug
D-Cycloserine
Placebodrug
Sugar Pill